Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Padcev
Pharma
Kyowa, Sino Biopharm, Duality—Fierce Pharma Asia
Kyowa Kirin ended its autoimmune program after new cancer reports. Sanofi linked up with Sino Biopharm. BioNTech advanced a DualityBio ADC. And more.
Angus Liu
Mar 6, 2026 9:35am
Padcev-Keytruda combo wins in MIBC amid evolving landscape
Feb 27, 2026 10:00am
Astellas lifts forecast as Vyloy surge counters trial miss
Feb 5, 2026 11:00am
Astellas CEO resists 'rescue BD' as Xtandi patent cliff nears
Jan 15, 2026 10:42am
Keytruda, Padcev keep winning streak in bladder cancer
Dec 17, 2025 9:53am
FDA safety probe, Otsuka, ADC patent fight—Fierce Pharma Asia
Dec 5, 2025 8:45am
